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Abstract 
Diabetic nephropathy (DN) is characterized by excessive extracellular matrix (ECM) 
accumulation that results in renal scarring leading to end stage kidney failure.  
Previous studies suggest that tissue transglutaminase (TG2) through formation of its 
protein crosslink product, -(-glutamyl) lysine, alters ECM homeostasis and causes 
basement membrane thickening and expansion of the mesangium and interstitium.  To 
determine if transglutaminase (TG) inhibition was able to slow the progression of 
chronic experimental DN over an extended treatment period, TG inhibitor NTU281 
was applied to streptozotocin (STZ)-induced diabetic uninephrectomy rats for up to 8 
months. 
Effective TG inhibition reduced the increases in serum creatinine (-68%) and 
albuminuria (-80%) in the diabetic rats.  These improvements were accompanied by a 
5 fold decrease in glomerulosclerosis and 6 fold reduction in tubulointerstitial 
scarring.  This was associated with reduced collagen IV accumulation by 4 months, 
and collagen I & III by 8 months.  In addition, TG inhibition lowered the numbers of 
myofibroblasts suggesting TG2 may play a role in myofibroblast transformation.  In 
conclusion TG inhibition ameliorates the progression of experimental DN and can 
therefore be considered as a prime candidate to be developed for clinical application. 
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Introduction 
Diabetic nephropathy (DN) is the most common cause of end-stage renal disease 
(ESRD) [1, 2] accounting for 50% of cases requiring renal replacement therapy 
(RRT) in the USA [3].  This is due to the increasing prevalence of type 2 diabetes and 
the reduced mortality of DN patients resulting from better management.  Diabetic 
patients now live longer and patients with diabetic ESRD are now being accepted for 
treatment in dialysis programs where formerly they may have been excluded.   
Clinically, the progression of DN is accompanied by the development of proteinuria 
and early glomerular hyperfiltration followed by a decline of glomerular filtration rate 
(GFR).  Morphologically, it is characterised by excessive renal extracellular matrix 
(ECM) accumulation in the glomeruli and tubulointerstitial space causing 
glomerulosclerosis and tubulointerstitial fibrosis.  This ultimately leads to ESRD.   
TG2 is a calcium dependent enzyme that catalyzes an acyl-transfer reaction (EC 
2.3.2.13) between the -carboxamide group of peptide-bound glutamine and the -
amino group of peptide-bound lysine.  This leads to the formation of a stable and 
proteolytic-resistant -(-glutamyl) lysine dipeptide bond resulting in intra- or inter- 
molecular crosslinks in protein.  A number of extracellular proteins including 
fibronectin [4], collagen [5], fibrinogen [6], osteopontin [7], laminin and nidogen [8] 
are TG2 substrates.  When TG2 is released from the cell, the high extracellular Ca2+ 
and low GTP (which modulates Ca2+ activation of the enzyme) activates the enzyme, 
enabling crosslinking of these ECM proteins at the cell surface and in the surrounding 
matrix.  Crosslinking of collagen by TG2 has been associated with stabilisation of the 
collagen fibril independently of lysyl oxidase [5], accelerated ECM deposition [9], 
reduced proteolytic breakdown of the ECM [10] and ultimately lower ECM turnover 
[11].  Thus TG2 action shifts the ECM deposition-degradation balance towards 
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accumulation [12] and has subsequently been linked to a range of fibrogenic 
conditions.   
A role for TG2 in the pathogenesis of DN has been reported in both the streptozotocin 
(STZ)-induced model of type 1 diabetes [13] and human diabetic kidney disease [14], 
with increased TG2 mediated -(-glutamyl) lysine crosslink formation in diabetic 
kidneys tightly associated with both glomerular and tubulointerstitial ECM expansion.  
Currently, there remains no viable mechanism for interfering with this ECM build up.  
Subsequently the development of therapeutic approaches directly targeting this 
process may provide an effective approach to the prevention of DN as well as 
numerous other fibrotic conditions.  The inhibition of TG activity in proximal tubular 
epithelial cells in culture has already been shown to reduce glucose-induced ECM 
accumulation [15] providing strong support for in vivo application of such compounds 
in the treatment to DN.  Therefore, in this study the TG site directed irreversible 
inhibitor N-benzyloxycarbonyl-L-phenylalanyl-6-dimethylsulfonium-5-oxo-L-
norleucine (NTU281) has been applied by direct intra-renal infusion into the kidneys 
of rats receiving STZ injection and uninephrectomy over an 8-month treatment 
period.  NTU281 is a benzyloxycarbonyl phenylalanyl analogue containing a 
dimethylsulfonium group that binds the cysteine residue in the active site of TG to 
instigate an acetonylation reaction leading to permanent non competitive inhibition of 
the enzyme [16].  Whilst the STZ model is not directly representative of DN in 
humans as it lacks the characteristic histological lesions, it is a useful surrogate for the 
impact of sustained hyperglycaemia on changes in ECM turnover in the kidney.  
Uninephrectomy has been used to accelerate diabetic kidney changes [17, 18].  We 
report TG inhibition can preserve kidney function, reduce albuminuria and ameliorate 
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the progression of the histological changes associated with the formation of scar tissue 
in DN. 
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Results 
Verification of drug delivery 
To ascertain if the intra renal cannulation was achieving uniform drug delivery 
throughout the kidney we prepared a dansyl labelled version of NTU281.  Using a 
kidney that was cannulated 28 days previously (to allow the fibrous coat around the 
cannula to develop) and had received PBS from implant, we infused 50mM dansyl 
labelled NTU281 for 24 hours.  Cryostat sections viewed under a fluorescent 
microscope demonstrated a uniform distribution of dansyl NTU281 in both the 
longitudinal and transverse planes in comparison to the contralateral kidney where no 
fluorescence was visible (Figure 1A).  Import of images into multi analyst image 
analysis software allowed densitometric profile assessment of the fluorescence which 
confirmed equal distribution in both planes (Figure 1B).  
Experimental groups 
4 experimental groups were used.  Normal, uninephrectomy (UNx), UNx + 
Streptozotocin (STZ) (referred to as diabetic or DM) and UNx + STZ + 
Transglutaminase inhibitor NTU281 (referred to as diabetic treated). 
General Observations 
Calculation of osmotic pump delivery rates from residual pump volumes 
demonstrated consistent drug delivery throughout the treatment period [Figure 2(i)].  
Examination of cannulas at termination indicated all had remained in situ and there 
was no evidence of cannula leakage.   
Compared to  normal and UNx animals, both diabetic groups (i.e. treated & untreated 
with NTU281) had higher levels of blood glucose throughout the experimental period 
[Figure 2 (iii)], and within the 10-25 mmol/L target range using a comparable insulin 
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dose [Figure 2(ii)] thus demonstrating an equal metabolic burden in treated and 
untreated rats.   
In hyperglycaemic animals by 8 months post STZ, body weight gain was 
approximately 2 fold lower [Figure 2(iv)] than in normal rats reaching 355±12.8g and 
377±14.3g in diabetic and NTU281 treated diabetic rats respectively compared to 
546±22.6g in normal (Table 1). 
Kidney weight following UNx was greater than normal, but only significantly at 1 
month post STZ (Table 1).  Imposing hyperglycaemia caused a marked increase in 
kidney weight being more than 3 fold greater by 8 months, however TG inhibition 
reduced increased kidney weight by 42% at this point (Table 1). 
Although blood pressure was raised in hyperglycaemic animals, there was no 
significant difference in systolic blood pressure between the 4 groups through the 
study (not shown). 
 
Effectiveness of TG Inhibition 
TG in situ activity assays showed a 6-fold increase in extracellular TG activity in the 
untreated diabetic animals by 8 months [Figure 3(i)].  Increased extracellular TG 
activity was present both in the glomeruli and tubulointerstitial compartments [Figure 
3(ii)].  In comparison, the extracellular TG activity in the NTU281-treated diabetic 
rats remained similar to that in both normal and uninephrectomy (UNx) controls 
throughout [Figure 3(i)].  In agreement with less extracellular TG activity in treated 
animals were lower levels of catalysed -(-glutamyl) lysine crosslinking (P<0.05) 
which were unaltered compared to the normal and UNx controls throughout the 
experimental period [Figure 3(iii)] demonstrating continuous effective TG inhibition.  
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Kidney Function and Albuminuria 
Kidney function was assessed using serum creatinine.  In untreated diabetic animals, 
serum creatinine rose throughout the experimental period with more than a 3.5-fold 
increase by 8 months compared to controls [Figure 2 (v)].  Although a small increase 
in serum creatinine (P<0.05) was detected in the NTU281-treated diabetic rats by 8 
months, this was 68.0% lower than those receiving no treatment (P<0.05).   
Measurement of 24-hour albumin excretion showed substantial increases in both 
treated and untreated diabetic groups by 4 months (P<0.05) that progressively 
increased at 8 months (P<0.05).  However, in NTU281-treated animals the increase in 
24-hour albumin excretion was lowered by approximately 80% at the end point 
[Figure 2 (vi)] suggesting that TG inhibition slows down the deterioration of 
glomerular structure and function.   
 
Kidney Scarring and Morphology 
After 1 month of hyperglycaemia, there was no substantial difference 
morphologically between the four experimental groups (Figure 4A-D).  By 4 months, 
kidney hypertrophy was well established in the UNx, treated and untreated diabetic 
kidneys with the largest increment occurring in the diabetic groups (Figure 4E-H).  
Furthermore, in the untreated diabetic kidney, both tubular atrophy as well as 
peritubular fibrosis was noted (Figure 4G).   
No evidence of interstitial fibrosis was seen at 8 months in the normal (Figure 4I) and 
UNx (Figure 4J) kidneys.  In comparison, in the untreated diabetic kidney (Figure 
4K), there was extensive epithelial flattening, tubular atrophy and interstitial 
expansion with severe tubulointerstitial scarring.  Nearly all glomeruli showed 
advanced glomerulosclerosis with Bowman’s space filled with collagen.  There was 
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extensive expansion of the mesangial matrix, the capillary network had collapsed and 
the glomeruli were extensively vacuolated.  In comparison, all these changes were 
dramatically reduced in the NTU281 treated diabetic kidneys (Figure 4L), with only 
mild focal tubular epithelial flattening and some minor expansion of the tubular 
basement membrane. 
Transmission electron microscopy of glomeruli in 8 month kidneys demonstrated 
significant widespread changes in both the glomerular basement membrane (GBM) 
and podocytes in untreated diabetic kidneys (Figure 5A).  There was a visible 
thickening of the GBM and most noticeably an effacement /loss of the podocytes 
especially visible at high power (Figure 5B).  Tg inhibition prevented the effacement / 
loss of podocytes while computerised morphometric assessment of GBM thickness 
demonstrated the diabetic induced GBM thickening was prevented with TG inhibition 
(Figure 5C).  
 
Quantification of Kidney Scarring  
Computerised multiphase image analysis was used to assess the degree of kidney 
scarring on Masson’s Trichrome stained sections.  Assessment of glomerulosclerosis 
[Figure 6(i)] showed a significant increase in the level of fibrous tissue present by 4 
months post hyperglycaemia that progressed significantly by 8 months in untreated 
diabetic kidneys being 5 fold that in control groups.  NTU281 treated kidneys showed 
no significant increase in glomerulosclerosis compared to normal and UNx glomeruli 
over the 8 month period. 
Tubulointerstitial fibrosis showed a similar trend to glomerulosclerosis with 2 fold 
increase in scarring at 4 months rising to 6 fold by 8 months in untreated diabetic 
animals [Figure 6(ii)].  NTU281 significantly reduced scarring in diabetic kidneys 
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with no detectable change compared to control at 4 months and only a 2 fold increase 
by 8 months.   
 
Kidney Collagen Content 
Whole kidney collagen was undertaken by measuring hydroxyproline in hydrolysed 
kidney homogenates.  By 8 months post STZ, the hydroxproline constituted 
0.89±0.04% of total amino acids in untreated hyperglycaemic kidneys and double 
those in normal (0.42±0.03%) and UNx animals (0.48±0.03%).  In NTU281 treated 
diabetic kidneys, hydroxyproline rose by just half that in the untreated diabetics 
reaching 0.67±0.03%.   
Changes in collagens, type I, III and IV were investigated by immunofluorescense.  In 
early experimental DN (1 and 4 months), there was no significant change in either 
collagen I [Figure 7(i)] or III [Figure 7(ii)] staining in the kidney between the 4 
experimental groups.  By 8 months, both collagen I [Figure 7(i)] and III [Figure 7(ii)] 
were elevated in the untreated diabetic kidney (P<0.05).  Increased collagen I was 
mainly found in sclerotic glomeruli (Figure 8C) while elevated collagen III occurred 
in the expanded interstitium and in periglomerular areas (Figure 8G).  In contrast, 
levels of both collagens in the NTU281 treated diabetic kidney remained similar to 
normal.  Collagen IV was significantly increased by 4 months in the untreated 
diabetic kidney (P<0.05) and continued to increase predominantly in peritubular and 
periglomerular areas (Figure 8K) at 8 months (P<0.05).  NTU281 treated diabetic 
kidneys had collagen IV staining levels that were comparable to the normal and UNx 
animals throughout experimental period [Figure 7(iii)].   
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Levels of kidney scarring significantly correlated with changes in accumulation of 
collagen I (r=0.515, P<0.01), collagen III (r=0.718, P<0.01) and collagen IV (r=0.570, 
P<0.01).   
 
mRNA Levels of Collagen I, III and IV 
To detect if the TG inhibition had an effect on collagen synthesis, Northern blotting 
was performed using 4 and 8-month kidneys. 
At 4 months, collagen I mRNA levels in the treated diabetic kidney were similar to 
normal, but higher than the UNx and untreated diabetic kidneys [Figure 9(i)].  By 8 
months, collagen I mRNA levels in diabetic kidneys were significantly higher than 
that in the normal and UNx [Figure 9(i)].  The NTU281 treated kidney had levels not 
significantly different from the untreated diabetic kidney [Figure 9(i)].  
The collagen III mRNA levels in the untreated diabetic kidney reached 5 fold higher 
than those in the normal and UNx by 8 months [Figure 9(ii)].  In contrast, the levels in 
the NTU281 treated kidney were normalised at this stage, although they had been 
higher than those in the untreated diabetic kidney at the earlier time point [Figure 
9(ii)].  
The collagen IV mRNA levels in both treated and untreated diabetic groups were 
similar and higher than the UNx at 4 months post STZ administration [Figure 9(iii)].  
By 8 months, it was significantly increased in the untreated diabetic kidney compared 
to the other 3 experimental groups with the levels more than double normal [Figure 
9(iii), P<0.05].  Although the treated group had levels higher than the normal, it was 
not significant [Figure 9(iii)]. 
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Overall, the above results suggested that the TG inhibitor, NTU281, had minimal 
effect on collagen I mRNA levels, but reduced the collagen III and IV mRNA levels 
by the end of the study. 
 
Myofibroblasts (-Smooth Muscle Actin Positive Cells)  
Less interstitial cells were observed on Masson’s Trichrome stained sections in the 
TG inhibitor treated kidney than the untreated.  ECM producing myofibroblasts have 
been reported to be associated with the progression of fibrosis in DN [19, 20].  
Therefore the abundance of these cells was determined using -smooth muscle actin 
(SMA) as a marker. 
At 1 month there were no substantial changes in SMA staining between any of the 
experimental groups, although significant increases in -SMA staining were detected 
in tubulointerstitial space of both treated and untreated diabetic kidneys by 4 months 
[Figure 7(iv)].  This continued to increase at 8 months [Figure 7(iv)] in the untreated 
group (Figure 8O).  However, levels in the treated diabetic group were 67% lower 
than that in the untreated diabetic kidney (P<0.05) suggesting TG inhibition reduced 
the accumulation of myofibroblasts in advanced DN. 
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Discussion 
All current TG inhibitors block not only TG2 activity, but also other TGs such as 
factor XIIIa, TG1 and TG3.  Hence, there is the potential for non specific effects that 
could complicate data interpretation.  For example, loss of keratinocyte TG (TG1) 
activity has been reported to cause parakeratosis and psoriasis like symptoms when 
applied to skin composites [21, 22] while blocking factor XIIIa may potentially lead 
to systemic effects such as haemorrhage and bleeding.  To overcome this, we 
employed NTU281, an inhibitor designed to act on the outside of the cell [23] limiting 
its targets to TG2 and factor XIIIa which are the only two forms of mammalian TG 
known to be secreted into the extracellular space.  Other potential targets such as 
cysteine proteases are in the main intracellular in nature while concentrations up to 1 
mmol/L of NTU281 do not inhibit other important cysteine containing enzymes such 
as caspase 3.  In addition, osmotic minipumps were employed to enable direct 
delivery of TG inhibitor to the kidney to minimise dose and hence systemic effects.  
Pressures generated by these pumps ensure blockage is unlikely which is supported by 
stable drug delivery volumes over the 8 months.  Application of dansyl labelled 
NTU281 demonstrated uniform distribution of drug within the receiving kidney by 
this method.  Administration of 50 mmol/L NTU281 from an implantable osmotic 
pump at 2.5 l/hour to the remnant kidney in the 5/6th neprectomy (SNx) model has 
previously shown to halt increases in kidney TG activity without affecting blood clot 
stability or TG activity in other organs such as heart, liver and skin (unpublished 
data).  Therefore, the same dose of NTU281 was used in this study and proved 
equally effective in reducing TG crosslinking activity in the diabetic kidney 
throughout the study as shown by both the reduction in TG in situ activity and 
crosslink levels which were uniform across the treated kidney. 
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TG inhibition resulted in preservation of kidney function and a reduction in 
albuminuria as a consequence of lower levels of both glomerulosclerosis and 
tubulointerstitial fibrosis.  On commencing this study, we expected that the 
underlying mechanism would be related to changes in ECM accumulation by 
blocking the post translational processing of the ECM by extracellular TG given that 
in vitro studies have repeatedly shown that TG2 alters ECM homeostasis by 
accelerating the rate of collagen deposition [12] and conferring the ECM with 
resistance to MMP proteolysis [10].  In keeping with this we see marked reductions in 
mature deposited collagen I, III and IV levels in the NTU281 treated diabetic kidneys.  
The levels of collagen I mRNA remained high with levels between untreated and 
NTU281 treated groups identical  In contrast, levels of collagen IV mRNA were 37% 
lower in the treated group and collagen III mRNA similar to normal animals by 8 
months    The collagen type I mRNA data clearly support a post-transcriptional 
mechanism (as predicted) in the presence of a continual fibrotic stimuli for collagen I, 
but the additional, unanticipated and interesting effect of NTU281 in suppressing type 
III and IV collagen mRNA levels is suggestive of an additional mechanism in 
lowering protein levels of these collagens.   
This study was not designed to  isolate particular mechanisms, and it therefore 
remains unclear from the data presented  whether these improvements are a direct 
result of TG inhibition or a secondary effect caused by the reduction in fibrous tissue 
expansion (and thus fibrotic stimuli) brought about by lowering TGase activity.  
However, one could hypothesise as to 2 mechanisms that could lead to lower levels of 
Collagen III and IV mRNA.  It has been reported that TG2 is able to activate the 
fibrogenic cytokine TGF-β1 by recruiting large latent TGF- in the ECM prior to 
proteolytic release of the active dimer [24, 25].  Therefore TG inhibition may affect 
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collagen synthesis by simply altering latent TGF-β1 activation, and this may be the 
case for collagen III and IV although other in vivo (unpublished data) and in vitro [15] 
studies using TG inhibitors have failed to demonstrate lower active TGF- levels.  
Alternatively, tubular ischemia caused by ECM expansion reducing blood flow to 
renal tubules may be less pronounced following NTU281 treatment.  The reduction in 
levels of tubulointerstitial fibrosis in the treated diabetic kidney may therefore allow 
better perfusion of the tubular epithelium lowering the hypoxia-inducible factor 
mediated induction of ECM proteins [26]. 
 
Apart from the reduction in ECM accumulation, another marked effect of TG 
inhibition was the preservation of tubulointerstitial architecture with less tubular 
atrophy and interstitial myofibroblasts.  Myofibroblasts undergo substantial 
proliferation and synthesize high levels of ECM proteins being central to the 
development of tubulointerstitial scarring and fibrosis [27-29].  Again it remains 
unclear from our data whether these improvements are a direct result of TG inhibition 
or secondary to the reduction in ECM expansion.   
TG inhibition was associated with a big improvement in albuminuria indicating 
protection of glomerular structure.  Electron microscopy of glomeruli clearly showed 
that TG inhibition was extremely effective in preservation of podocytes.  Untreated 
animals had essentially no visible podocytes on the GBM indicating either loss or 
pedicel retraction whereas those receiving NTU281 had a podocyte structure and 
number that was not discernable from both control groups.  The reason for this is most 
likely a combination of qualitative changes to the GBM (such as from the inclusion of 
collagen 1) and the 50% thicker GBM shown by morphometric measurements. 
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Lower levels of interstitial -SMA positive cells in NTU281 treated kidneys are 
suggestive of a reduction in myofibroblast levels, although -SMA is not specific for 
myofibroblasts with smooth muscle cells in the vasculature being particularly evident 
in the kidney.  Epithelial-mesenchymal transdifferentiation (EMT) is thought to be a 
major contributor to interstitial fibrosis [30, 31] and thus a reduction in this could 
account for lower -SMA staining.  As previously mentioned, TG is known to play a 
role in latent TGF- activation.  Given TGF- has been reported to be the most 
potent inducer of tubular epithelial cell EMT [32], it could be hypothesised that the 
increased TG activity in the diabetic kidney causes a rise in active TGF- 
availability resulting in the activation of myofibroblast.  TG inhibition may reduce the 
presence of myofibroblasts by blocking TG dependent TGF- activation pathway 
[10, 13, 33].   
Of note was the variation in kidney TG activity in the untreated diabetic in this model.  
Both control groups plus the NTU281 treated kidney showed no significant change in 
TG activity over the 8 months.  In contrast the DM group had a 4 fold increase at 1 
month, returned to near normal at 4 months with a 3 fold increase by 8 months. After 
repeating this assay several times we believe that this genuinely reflects a bi-phasic 
response of TG2.  An early acute response to the hyperglycaemia which may 
predominantly reflect a synthesis independant cell export of TG2 as described 
previously in early DN [13], followed by a late remodelling response which is TG2 
synthesis dependant as reported in aggressive fibrosis [10].  The discrepancy between 
-glutamyl) lysine crosslink levels and TG2 activity may seem contradictory, but is 
not surprising.  TG2 has a half life of around 8 hours so is quickly cleared while the 
-glutamyl) lysine crosslink TG2 produces is very stable requiring complete 
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digestion of the tissue to release it.  Thus if TG2 activity decreased the crosslink 
would remain high.   
In conclusion TG inhibition dramatically slows the development of experimental DN 
via reduction in tubulointerstitial fibrosis and glomerulosclerosis.  This preserves 
kidney function and slows the development of proteinuria.  The prime mechanism for 
this is most likely to be the lowering of the direct action of TG on ECM crosslinking 
that leads to matrix accumulation.  The data suggests that TG inhibitors offer a 
potential therapeutic avenue for the amelioration of DN in the diabetic patient, 
however clinical application is likely to be dependent on the development of isoform 
specific compounds.   
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METHODS 
Synthesis of TG inhibitor 
NTU281 was synthesised according to published methods [15].  Compound purity 
was determined by NMR and mass spectrometry.  Inhibitor efficacy was verified 
against renal TGs by application of the inhibitor at 100 and 500mol/L to a 20% 
kidney homogenate with activity measured using the [14C] putrescine incorporation 
assay. 
Experimental animals and protocol 
Male Wistar Han rats (Harlan, UK) of 200 to 250g and 8 to 10 weeks old were 
subjected to right uninephrectomy (UNx).  Seven days later hyperglycaemia was 
induced by tail vain injection of STZ (35mg/kg in citrate buffer, pH 4.0).  Control 
animals were subjected to either a sham operation or UNx with vehicle injection 
alone.  An early morning blood glucose level above 10 mmol/L at 1 week after STZ 
injection was considered diabetic. Blood glucose was controlled between 10 to 25 
mmol/L using insulin implants (Research Pack, LinShin, Canada).  Practically, 1/4 
insulin implant was progressively inserted subcutaneously (using a trocar) until the 
target glucose range was reached.  Measurements were taken 48 hours after each 1/4 
implant was inserted using a One Touch Basic glucose meter (Johnson and Johnson).  
Blood glucose measurements were repeated biweekly with replacement implants 
inserted as required. 
A 0.58mm bore polyethylene cannula was heat-sealed at one end and fenestrated 
between 2 and 12mm from the seal.  The open end was attached to a 2ML4 mini 
osmotic pump (Alzet, USA).  At UNx, the cannula was passed longitudinally through 
the remaining kidney such that all perforations were within the renal parenchyma.  
The cannula was secured using silk ties and tissue glue and run through the muscle 
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wall to the pump located on the scruff.  Pumps were loaded with either PBS (vehicle) 
or 50 mmol/L solution of NTU281 and replaced every 28 days when exhausted.  
Rats were housed 1 to 4 to a cage at 20-22°C and 45% humidity on a 12 hours 
light/dark cycle.  They were allowed free access to standard rat chow (Labsure Ltd., 
Cambridge, United Kingdom) and tap water.  Animals were divided into 4 groups: 
normal, uninephrectomy (UNx), diabetes with UNx (UNx+DM) and diabetes with 
UNx treated with NTU281 (UNx+DM+NTU281).  At 1, 4 and 8 months after STZ 
injection, rats were killed and kidneys removed from both diabetic groups (n ≥ 6) and 
controls (n = 4) groups.  Serum creatinine was measured by standard autoanalyzer 
technique and 24-hour albuminuria by using the Bethyl Laboratories rat albumin 
ELISA kit (BioGnosis, Hailsham, UK) following the manufacturer’s instructions.  All 
procedures were carried out under license according to regulations laid down by Her 
Majesty’s Government, United Kingdom (Animals Scientific Procedures Act, 1986). 
NTU281 distribution 
To ensure adequate distribution through the kidney, NTU281 was synthesised with a 
Dansyl label.  Animals cannulated as above were infused with PBS for 1 month for 
the maximum fibrous coat to develop around the cannula (Figure 1A) at which stage 
kidneys were infused with 50mM Dansyl-NTU281 for 24 hours as above.  Kidneys 
were removed and halved longitudinally along the cannula.  Cryosections were cut at 
10 m and Dansyl visulaised under a FITC filter on a fluorescent microscope using 
the contralateral kidney as a control.  Analysis 3.2 image analysis software (Soft 
imaging Systems, Germany) was used to generate a full length & width images using 
multi field alignement.  These were imported into Multi Analyst (Biorad) and a 
densitometric profile generated. 
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Detection of In Situ TG Activity 
Cryostat sections were incubated with 0.5mmol/L biotin cadaverine (Molecular 
Probes, Netherlands) and 5mmol/L CaCl2.  A negative control in which CaCl2 was 
replaced with 10mmol/L EDTA was used.  Incorporated biotin cadaverine was 
revealed by immunoprobing with a streptavidin indodicarbocyanine (Cy5) conjugate 
(Jackson ImmunoResearch, USA) at 1 in 50 dilution.  Sections were visualized using 
a Leica TCS NT confocal microscope (Leica DMRBE; Lasertechnik, Wetzlar, 
Germany) using a Kr/Ar laser (647 and 488 nm) for both Cy5 (optimal excitation 650 
nm) and autofluorescence.  Computer imaging was obtained at 665 and 530 nm for 
Cy5 and autofluorescence, respectively (Leica TCS NT, Lasertechnik).  Cadaverine 
incorporation was assessed on 6 cortical fields at 100× magnification acquired using a 
CC-12 digital camera (Soft Imaging Systems, Germany).  Multiphase image analysis 
(AnalysisTM 3.2, Soft Imaging Systems) was performed to assess levels of 
incorporated cadaverine by dividing the area of red cadaverine stain with the green 
tissue autofluorescence to correct for tissue mass.   
Detection of -glutamyl)-lysine Crosslink 
The determination of -glutamyl)-lysine Crosslink was similar to previously 
described [13].  Cryostat sections were incubated with a mouse monoclonal anti-- (-
glutamyl) lysine isopetide antibody (81-D4; Covalab, Lyon, France) or mouse 
nonimmune serum (DAKO) at 1 in 20 dilution.  After washing and fixing, primary 
antibody was revealed using a donkey anti-mouse Cy5-conjugated antibody (Jackson 
ImmunoResearch, USA).  Section visualization and multiphase image analysis were 
performed as described above.   
Fibrosis Measurement 
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4m, neutral buffered formalin fixed, paraffin embedded sections were stained with 
Masson’s trichrome (stains collagenous material blue, nuclei, fiber, erythrocytes and 
elastin red/pink).  For glomerulosclerosis and tubulointerstitial scarring, 20 glomeruli 
(400×) and 10 fields (200×) of cortex tubules were acquired respectively in a 
systematic manner.  A fibrous coat can develop around the renal cannula which can 
extend up to 1 mm in thickness (Figure 1, Masons Trichrome insert).  In sections 
immediately above or below the cannula path, affected fields are excluded from 
analysis to avoid data contamination.  Fibrosis was assessed using multiphase image 
analysis [34].  The fibrosis index was determined by dividing the area of blue 
collagenous stain by red cellular stain thus correcting for cell number. 
Immunofluorescent Measurements 
Immunofluorescent staining was carried out on 4m paraffin sections using a 
secondary antibody conjugated with fluorescein isothiocyanate (FITC) (DAKO).  
Following antigen retrieval, primary antibodies were applied as follows: goat anti-
collagen (1) III (1:10; Southern Biotech, USA), rabbit anti-collagen IV (1:35; ICN, 
USA) and mouse anti-SMA (1:100, DAKO, UK).  Collagen I immunofluorescence 
was performed on 10 m cryostat sections using a mouse anti-collagen (1) I 
antibody (1:50; Abcam, UK).  Collagen IV antibodies were not chain specific 
recognising 1, 2, 3 and 4 chains equally. 
10 cortical fields at 200× magnification of each section were acquired.  These were 
analysed using multiphase image analysis as above with correction to DAPI staining. 
Electron Microscopy 
Tissue from paraffin blocks was recovered, post fixed in gluteraldehyde and subjected 
to transmission electron microscopy as previously described [35] using magnification 
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at 2600x and 20 000x. GBM thickness was determined by taking at least 10 GBM 
measurements per glomeruli for each animal at 20,000 magnification using Kodak 
AMTv600 image analysis software. 
 
 
Measurement of mRNA Levels 
Total RNA was extracted using TRizolTM (Gibco, UK) and subjected to Northern blot 
analysis as previous described [36].  Autoradiographs were quantified by scanning 
densitometry using a Biorad GS-690 densitometer and Molecular Analyst version 4 
software.  Densitometry values were corrected for loading using the house keeping 
gene cyclophilin [36]. 
cDNA Probes 
Specific random primed DNA probes were constructed from the following sequences: 
human collagen (1) I [37], rat collagen (1) III [38] and human collagen (1) IV 
[39]. 
Hydroxyproline Analysis 
400μl of 10% Kidney Homogenates were hydrolysed in 6M HCl at 110°C for 18 
hours.  These were clarified by centrifugation at 14,000rpm for 2 minutes and 20μl 
fractionated using a lithium chloride gradient on a Biochrom 30 amino acid analyser 
as optimised by the manufacturer (Biochrom, UK).  Hydroxyproline was identified 
against an amino acid standard and expressed as a percentage of total amino acids.   
Statistical Analysis 
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Data analyses were performed using one way ANOVA followed by a Bonferroni post 
hoc test.  A probability of 95% (p<0.05) was taken as significant.  Correlation 
analysis was performed on SPSS 12.0.1 for Windows.  
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Table 
Table 1:  Final body weight and terminal kidney weight. 
            Time 
Groups    
final body weight (g) terminal kidney weight (g) 
1-month 4-month 8-month 1-month 4-month 8-month 
Normal 36111.7 4728.6 54622.6 1.00.0 1.40.13 1.40.13 
UNx 3897.2 a 44714.2 51415.8 1.40.08 a  1.50.04 1.70.10 
UNx+DM 31913.4 a, b  35620.0 a, b 35512.8 a, b  1.70.17 a 3.10.30 a, b 5.70.91 a, b 
UNx+DM+NTU281 3206.7 a, b  35010.3 a, b 37714.3 a, b 2.30.25 a, b, c 2.80.36 a, b 3.30.25 a, b, c 
Data represents mean ± SEM, n=4-7 per group.  Significance (P<0.05) is indicated in 
comparison to normal (a), UNx(b), untreated DM (c). 
 
Titles and legends 
Figure 1.  NTU281 Distribution.   The kidney distribution of dansyl labelled 
NTU281 (Green) in both transverse and longitudinal planes from an intra 
parenchymal renal cannula inserted 28 days previously with 24 hours drug delivery 
from an implanted osmotic pump (A).  Inset shows effect of cannulation on renal 
morphology on a Masson’s Trichrome stained slide at 1 month.  Quantification of 
fluorescence in comparison to the contralateral kidney in both longitudinal (B) and 
transverse (C) planes.  
Figure 2: Hyperglycaemia,kidney function and drug delivery.  The volume of 
drug delivered per month was calculated from residual volumes in the pump (i). 
Insulin implants required to control blood glucose to 10-25 mmol/L were averaged for 
each experimental group (ii).  The average blood glucose of each animal over the 
monitoring period was determined (iii).  Changes in body weight (g) were calculated 
by subtracting the initial body weight from the final body weight at each time point 
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(iv).   Kidney function was assessed by measuring serum creatinine concentration 
(μmol/L) (v).  24-hour albumin excretion (mg) was used to assess glomerular damage 
(vi).  White circles = normal, black circles = UNx, white squares = untreated DM, 
black squares = NTU281 treated DM.  Data represents mean ± SEM, n=4-7 per group.  
Significance (P<0.05) is indicated in comparison to normal (a), UNx(b), untreated 
DM (c) and NTU281 treated DM (d). 
Figure 3: TG inhibition.  The effectiveness of NTU281 to reduce TG activity was 
assessed by measuring in situ TG activity using multiphase image analysis at 1, 4 and 
8 months post STZ (i).  Representative TG in situ activity confocal microscope 
images at 8 months for normal (A), UNx (B), DM (C) and DM+NTU281 (D) kidneys 
with TG activity shown in red (ii).  Inhibition was confirmed by determining TG 
catalysed -(-glutamyl) lysine crosslink staining again using multiphase image 
analysis (iii).  White circles = normal, black circles = UNx, white squares = untreated 
DM, black squares = NTU281 treated DM.  Data represents mean ± SEM, n=4-7 per 
group.  Significance (P<0.05) is indicated in comparison to normal (a), UNx(b), 
untreated DM (c) and NTU281 treated DM (d). 
Figure 4: Masson’s trichrome staining.  4m thick sections from 1month (A-D), 4 
months (E-H) and 8 months (I-L) post induction of hyperglycaemia were stained for 
Masson’s trichrome (40× magnification). 
Figure 5:  Glomerular Electron Microscopy.  Paraffin embedded tissue from 8 
month experimental groups was post fixed in gluteraldehyde and observed by 
transmission electron microscopy at 2,600 (A) and 20,000 (B) magnification.  
Glomerular basement membrane (GBM) thickness was measured by computerised 
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morphometric analysis by a pathologist blinded to experimental groups (C).  Data 
represents mean GBM thickness ± SEM. *=Significance from normal (p<0.05) 
Figure 6: Glomerulosclerosis and tubulointerstitial scarring.  Glomerulosclerosis 
(i) and tubulointerstitial scarring (ii) were assessed by multiphase image analysis of 
Masson’s trichrome stained sections.  20 glomeruli (400× magnification) or 10 
cortical tubulointerstitial fields (200× magnification) were analysed respectively per 
section.  White circles = normal, black circles = UNx, white squares = untreated DM, 
black squares = NTU281 treated DM.  Data represents mean ± SEM, n=4-7 per group.  
Significance (P<0.05) is indicated in comparison to normal (a), UNx(b), untreated 
DM (c) and NTU281 treated DM (d). 
Figure 7: Quantification of collagen I, III, IV and -SMA immunostaining.  
Kidney levels of collagen I (i), collagen III (ii), collagen IV (iii) and -SMA (iv) 
staining (Figure 6) were assessed by multiphase image analysis of 10 fields per 
section.  White circles = normal, black circles = UNx, white squares = untreated DM, 
black squares = NTU281 treated DM.  Data represents mean ± SEM, n=4-7 per group.  
Significance (P<0.05) is indicated in comparison to normal (a), UNx(b), untreated 
DM (c) and NTU281 treated DM (d). 
 
Figure 8: Immunofluorescent staining of collagen I, III, IV and -SMA in 
kidneys 8-month post hyperglycaemia.  Collagen I staining (A-D) was performed 
on cryostat sections with collagen III (E-H), collagen IV (I-L) and -SMA (M-P) on 
paraffin sections.  Fields were acquired at 200× magnification on a Olympus BX61 
fluorescent microscope using a FITC and DAPI filter sets. 
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Figure 9:  Northern blot analysis of collagen I, III and IV mRNA.  mRNA levels 
of collagen I (i), collagen III (ii) and collagen IV (iii) were assessed by Northern blot 
analysis using volume densitometry measurements normalised to the house keeping 
gene cyclophilin (iv).  Some displayed autoradiographs are over exposed for diseased 
groups to allow clear visualisation in normal kidneys White circles = normal, black 
circles = UNx, white squares = untreated DM, black squares = NTU281 treated DM.  
Data represents mean optical density ± SEM, n=4-7 per group.  Significance (P<0.05) 
is indicated in comparison to normal (a), UNx(b), untreated DM (c) and NTU281 
treated DM (d).   
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